Market Definition
The U.S. Early Toxicity Testing Market was valued at USD 2.42 billion in 2022, and is predicted to reach USD 4.14 billion by 2030, with a CAGR of 6.02% from 2023 to 2030.
Early toxicity testing is a fundamental procedure encompassing the evaluation of potential toxicity or detrimental impacts arising from drugs, chemicals, or various substances during their preliminary developmental phases. This assessment predominantly occurs through in vitro studies or animal models before human trials commence.
The overarching objective of early toxicity testing is to promptly uncover any safety-related apprehensions linked to a substance, thus facilitating informed decisions about its feasibility for continued development and subsequent testing.
By conducting early toxicity testing, the risks of adverse effects on both human subjects and animals during clinical trials are mitigated, simultaneously curtailing expenses and time invested in the overall drug development trajectory. This intricate process encompasses a gamut of examinations and assays, encompassing cell viability assessments, genotoxicity evaluations, and pharmacokinetic investigations.
The specific modalities employed are contingent on the intrinsic nature of the substance under scrutiny and its intended application. Recognized as an indispensable phase within the drug development journey, early toxicity testing profoundly bolsters the assurance of safety and efficacy for novel drugs and other substances, prior to their regulatory endorsement for human utilization.
Robust Healthcare Infrastructure and Cardiovascular Disease Prevalence in the U.S. is Driving the Market Growth
The early toxicity testing market is growing, owing to robust healthcare infrastructure, high investment in R&D, and increase in demand for high-quality pharmaceutical products in the U.S.
For instance, according to the Centers for Medicare & Medicaid Services, the national healthcare expenditure reached 4.3 trillion in 2021 in the United States. In addition, the market is being driven by rise in prevalence of heart diseases, which is a leading cause of death in the U.S. and has been on the rise in recent years.
For instance, according to the Centers for Disease Control and Prevention (CDC), around 697,000 Americans died from heart disease in 2020, which is approximately 1 in every 5 deaths.
The Escalated Demand for High-quality Pharmaceuticals in the U.S. Propels Increased Investment in Early Toxicity Testing
In the dynamic landscape of healthcare, a notable paradigm shift has taken root within the United States, which resulted a transformation fuelled by the ever-increasing expectations of the population for pharmaceutical solutions that transcend mere functionality. This transformative trend centers around the resolute pursuit of high-quality, potent, and dependable pharmaceutical products that not only meet medical needs but also resonate with the deep-seated desire for safety and efficacy.
This palpable shift in consumer aspirations is serving as a transformative force, compelling pharmaceutical enterprises to recalibrate their strategies and invest more assertively in early toxicity testing. In essence, this strategic investment serves as the bedrock upon which the safety and reliability of pharmaceutical products are firmly anchored, thereby fostering a marked expansion of the early toxicity testing market in U.S.
Regulatory Constraints and their Impact on Early Toxicity Testing Market Growth in U.S.
However, stringent regulations set by regulatory bodies such as the US FDA and the EMA require extensive and rigorous testing for drug development and safety, which can be time-consuming and expensive and restrain growth of the market. The complexity and cost of complying with these regulations can pose a significant challenge for small and medium-sized companies that may not have the resources to carry out extensive testing.
As a result, some companies may choose to delay or abandon drug development projects, which can limit demand for early toxicity testing services. Moreover, stringent regulations can also result in a lengthy approval process for new drugs, further delaying the time it takes for drugs to reach the market. This, in turn, is expected to hamper growth of the market.
Technological Advancements in the field of Early Toxicity Testing Market in U.S.
Introduction of new technologies such as in-vitro modelling using 3D cell culture is expected to provide new lucrative opportunities for the early toxicity testing market during the forecast period.
Use of 3D cell cultures can better mimic complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. Traditional 2D cell culture models are limited in their ability to mimic complexity of human tissues and organs, often leading to inaccurate and unreliable results in toxicity testing.
However, use of 3D cell culture models can better mimic structural and functional complexity of tissues and organs, providing more accurate and reliable results for toxicity testing. 3D cell cultures allow growth and interaction of multiple cell types, creating a microenvironment that more closely resembles human tissues and organs. This can better predict toxic effects of drugs and chemicals in the human body, reducing the risk of adverse effects in clinical trials. Hence, such factors propel the market growth.
Competitive Landscape
The U.S. Early Toxicity Testing industry includes several market players such as Inotiv Inc., Bio-Rad Laboratories Inc, Evotec A.G., Agilent Technologies Inc, Wuxi Apptec, Bruker, Perkinelmer Inc., Enzo Biochem Inc., Danaher Corporation, Eurofins Scientific SE, Charles River Laboratories International, Inc., Labcorp Drug Development., Promega Corporation, Insphero AG., and Thermo Fisher Scientific Inc.
KEY BENEFITS
-
The U.S. Early Toxicity Testing market report provides a quantitative analysis of the current market and estimations through 2023-2030 that assists in identifying the prevailing market opportunities to capitalize on.
-
The study comprises a deep dive analysis of the market trend including the current and future trends for depicting the prevalent investment pockets in the industry.
-
The information related to key drivers, restraints, and opportunities and their impact on the market is provided in the report.
-
The competitive analysis of the key players along with their market share in the U.S. Early Toxicity Testing market.
-
The SWOT analysis and Porter’s Five Forces model are elaborated in the study.
-
Value chain analysis in the market study provides a clear picture of the stakeholders’ roles.
U.S. EARLY TOXICITY TESTING MARKET KEY SEGMENTS
By Technique
-
In Vivo
-
In Vitro
-
Cell Culture
-
PCR
-
ELISA
-
Western Blotting
-
Protein Binding Assays
-
In Silico
By Toxicity Endpoint
-
Genotoxicity
-
Dermal Toxicity
-
Skin Toxicity
-
Ocular Toxicity
-
Phototoxicity
-
Others
By End User
-
Pharmaceutical Industry
-
Cosmetic Industry
-
Chemical Industry
-
Food Industry
-
Others
REPORT SCOPE AND SEGMENTATION:
Parameters
|
Details
|
Market Size in 2022
|
USD 2.42 Billion
|
Revenue Forecast in 2030
|
USD 4.14 Billion
|
Growth Rate
|
CAGR of 6.02% from 2023 to 2030
|
Analysis Period
|
2022–2030
|
Base Year Considered
|
2022
|
Forecast Period
|
2023–2030
|
Market Size Estimation
|
Billion (USD)
|
Growth Factors
|
Healthcare infrastructure and cardiovascular disease prevalence.
Demand for quality pharmaceuticals.
|
Companies Profiled
|
15
|
Market Share
|
Available for 15 companies
|
Customization Scope
|
Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
|
Pricing and Purchase Options
|
Avail customized purchase options to meet your exact research needs.
|
Test
1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 RESEARCH METHODOLOGY
1.2.1 SECONDARY RESEARCH
1.2.2 DATA ANALYSIS FRAMEWORK
1.2.3 MARKET SIZE ESTIMATION
1.2.4 FORECASTING
1.2.5 PRIMARY RESEARCH AND DATA VALIDATION
2 U.S. EARLY TOXICITY TESTING MARKET BY TECHNIQUE
2.1 OVERVIEW
2.2 IN VIVO MARKET
2.3 IN VITRO MARKET
2.3.1 CELL CULTURE
2.3.2 PCR
2.3.3 ELISA
2.3.4 WESTERN BLOTTING
2.3.5 PROTEIN BINDING ASSAYS
2.4 IN SILICO MARKET
3 U.S. EARLY TOXICITY TESTING MARKET BY TOXICITY ENDPOINT
3.1 OVERVIEW
3.2 GENOTOXICITY MARKET
3.3 DERMAL TOXICITY MARKET
3.4 SKIN TOXICITY MARKET
3.5 OCULAR TOXICITY MARKET
3.6 PHOTOTOXICITY MARKET
3.7 OTHERS MARKET
4 U.S. EARLY TOXICITY TESTING MARKET BY END USER
4.1 OVERVIEW
4.2 PHARMACEUTICAL INDUSTRY MARKET
4.3 COSMETIC INDUSTRY MARKET
4.4 CHEMICAL INDUSTRY MARKET
4.5 FOOD INDUSTRY MARKET
4.6 OTHERS MARKET
5 COMPANY PROFILES
5.1 INOTIV INC.
5.1.1 COMPANY OVERVIEW
5.1.2 COMPANY SNAPSHOT
5.1.3 OPERATING BUSINESS SEGMENTS
5.1.4 PRODUCT PORTFOLIO
5.1.5 BUSINESS PERFORMANCE
5.1.6 BUSINESS SEGMENTS
5.1.7 GEOGRAPHIC SEGMENTS
5.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.1.9 PRIMARY MARKET COMPETITORS
5.2 BIO-RAD LABORATORIES INC
5.2.1 COMPANY OVERVIEW
5.2.2 COMPANY SNAPSHOT
5.2.3 OPERATING BUSINESS SEGMENTS
5.2.4 PRODUCT PORTFOLIO
5.2.5 BUSINESS PERFORMANCE
5.2.6 BUSINESS SEGMENTS
5.2.7 GEOGRAPHIC SEGMENTS
5.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.2.9 PRIMARY MARKET COMPETITORS
5.3 EVOTEC A.G.
5.3.1 COMPANY OVERVIEW
5.3.2 COMPANY SNAPSHOT
5.3.3 OPERATING BUSINESS SEGMENTS
5.3.4 PRODUCT PORTFOLIO
5.3.5 BUSINESS PERFORMANCE
5.3.6 BUSINESS SEGMENTS
5.3.7 GEOGRAPHIC SEGMENTS
5.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.3.9 PRIMARY MARKET COMPETITORS
5.4 AGILENT TECHNOLOGIES INC
5.4.1 COMPANY OVERVIEW
5.4.2 COMPANY SNAPSHOT
5.4.3 OPERATING BUSINESS SEGMENTS
5.4.4 PRODUCT PORTFOLIO
5.4.5 BUSINESS PERFORMANCE
5.4.6 BUSINESS SEGMENTS
5.4.7 GEOGRAPHIC SEGMENTS
5.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.4.9 PRIMARY MARKET COMPETITORS
5.5 WUXI APPTEC
5.5.1 COMPANY OVERVIEW
5.5.2 COMPANY SNAPSHOT
5.5.3 OPERATING BUSINESS SEGMENTS
5.5.4 PRODUCT PORTFOLIO
5.5.5 BUSINESS PERFORMANCE
5.5.6 BUSINESS SEGMENTS
5.5.7 GEOGRAPHIC SEGMENTS
5.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.5.9 PRIMARY MARKET COMPETITORS
5.6 BRUKER
5.6.1 COMPANY OVERVIEW
5.6.2 COMPANY SNAPSHOT
5.6.3 OPERATING BUSINESS SEGMENTS
5.6.4 PRODUCT PORTFOLIO
5.6.5 BUSINESS PERFORMANCE
5.6.6 BUSINESS SEGMENTS
5.6.7 GEOGRAPHIC SEGMENTS
5.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.6.9 PRIMARY MARKET COMPETITORS
5.7 PERKINELMER INC.
5.7.1 COMPANY OVERVIEW
5.7.2 COMPANY SNAPSHOT
5.7.3 OPERATING BUSINESS SEGMENTS
5.7.4 PRODUCT PORTFOLIO
5.7.5 BUSINESS PERFORMANCE
5.7.6 BUSINESS SEGMENTS
5.7.7 GEOGRAPHIC SEGMENTS
5.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.7.9 PRIMARY MARKET COMPETITORS
5.8 ENZO BIOCHEM INC.
5.8.1 COMPANY OVERVIEW
5.8.2 COMPANY SNAPSHOT
5.8.3 OPERATING BUSINESS SEGMENTS
5.8.4 PRODUCT PORTFOLIO
5.8.5 BUSINESS PERFORMANCE
5.8.6 BUSINESS SEGMENTS
5.8.7 GEOGRAPHIC SEGMENTS
5.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.8.9 PRIMARY MARKET COMPETITORS
5.9 DANAHER CORPORATION
5.9.1 COMPANY OVERVIEW
5.9.2 COMPANY SNAPSHOT
5.9.3 OPERATING BUSINESS SEGMENTS
5.9.4 PRODUCT PORTFOLIO
5.9.5 BUSINESS PERFORMANCE
5.9.6 BUSINESS SEGMENTS
5.9.7 GEOGRAPHIC SEGMENTS
5.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.9.9 PRIMARY MARKET COMPETITORS
5.10 EUROFINS SCIENTIFIC SE
5.10.1 COMPANY OVERVIEW
5.10.2 COMPANY SNAPSHOT
5.10.3 OPERATING BUSINESS SEGMENTS
5.10.4 PRODUCT PORTFOLIO
5.10.5 BUSINESS PERFORMANCE
5.10.6 BUSINESS SEGMENTS
5.10.7 GEOGRAPHIC SEGMENTS
5.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.10.9 PRIMARY MARKET COMPETITORS
5.11 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
5.11.1 COMPANY OVERVIEW
5.11.2 COMPANY SNAPSHOT
5.11.3 OPERATING BUSINESS SEGMENTS
5.11.4 PRODUCT PORTFOLIO
5.11.5 BUSINESS PERFORMANCE
5.11.6 BUSINESS SEGMENTS
5.11.7 GEOGRAPHIC SEGMENTS
5.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.11.9 PRIMARY MARKET COMPETITORS
5.12 LABCORP DRUG DEVELOPMENT.
5.12.1 COMPANY OVERVIEW
5.12.2 COMPANY SNAPSHOT
5.12.3 OPERATING BUSINESS SEGMENTS
5.12.4 PRODUCT PORTFOLIO
5.12.5 BUSINESS PERFORMANCE
5.12.6 BUSINESS SEGMENTS
5.12.7 GEOGRAPHIC SEGMENTS
5.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.12.9 PRIMARY MARKET COMPETITORS
5.13 PROMEGA CORPORATION
5.13.1 COMPANY OVERVIEW
5.13.2 COMPANY SNAPSHOT
5.13.3 OPERATING BUSINESS SEGMENTS
5.13.4 PRODUCT PORTFOLIO
5.13.5 BUSINESS PERFORMANCE
5.13.6 BUSINESS SEGMENTS
5.13.7 GEOGRAPHIC SEGMENTS
5.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.13.9 PRIMARY MARKET COMPETITORS
5.14 INSPHERO AG
5.14.1 COMPANY OVERVIEW
5.14.2 COMPANY SNAPSHOT
5.14.3 OPERATING BUSINESS SEGMENTS
5.14.4 PRODUCT PORTFOLIO
5.14.5 BUSINESS PERFORMANCE
5.14.6 BUSINESS SEGMENTS
5.14.7 GEOGRAPHIC SEGMENTS
5.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.14.9 PRIMARY MARKET COMPETITORS
5.15 THERMO FISHER SCIENTIFIC INC.
5.15.1 COMPANY OVERVIEW
5.15.2 COMPANY SNAPSHOT
5.15.3 OPERATING BUSINESS SEGMENTS
5.15.4 PRODUCT PORTFOLIO
5.15.5 BUSINESS PERFORMANCE
5.15.6 BUSINESS SEGMENTS
5.15.7 GEOGRAPHIC SEGMENTS
5.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
5.15.9 PRIMARY MARKET COMPETITORS
LIST OF TABLES
TABLE 1. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 2. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
TABLE 3. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
TABLE 4. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
TABLE 5. INOTIV INC.: COMPANY SNAPSHOT
TABLE 6. INOTIV INC: OPERATING SEGMENTS
TABLE 7. INOTIV INC.: PR0DUCT PORTFOLIO
TABLE 8. INOTIV INC.: BUSINESS SEGMENT
TABLE 9. INOTIV INC.: GEOGRAPHIC SEGMENT
TABLE 10. INOTIV INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 11. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
TABLE 12. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
TABLE 13. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
TABLE 14. BIO-RAD LABORATORIES INC: BUSINESS SEGMENT
TABLE 15. BIO-RAD LABORATORIES INC: GEOGRAPHIC SEGMENT
TABLE 16. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 17. EVOTEC A.G.: COMPANY SNAPSHOT
TABLE 18. EVOTEC A.G.: OPERATING SEGMENTS
TABLE 19. EVOTEC A.G.: PRODUCT PORTFOLIO
TABLE 20. EVOTEC A.G.: BUSINESS SEGMENT
TABLE 21. EVOTEC A.G.: GEOGRAPHIC SEGMENT
TABLE 22. EVOTEC A.G.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 23. AGILENT TECHNOLOGIES INC: COMPANY SNAPSHOT
TABLE 24. AGILENT TECHNOLOGIES INC: OPERATING SEGMENTS
TABLE 25. AGILENT TECHNOLOGIES INC: PRODUCT PORTFOLIO
TABLE 26. AGILENT TECHNOLOGIES INC: BUSINESS SEGMENT
TABLE 27. AGILENT TECHNOLOGIES INC: GEOGRAPHIC SEGMENT
TABLE 28. AGILENT TECHNOLOGIES INC: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 29. WUXI APPTEC.: COMPANY SNAPSHOT
TABLE 30. WUXI APPTEC: OPERATING SEGMENTS
TABLE 31. WUXI APPTEC.: PR0DUCT PORTFOLIO
TABLE 32. WUXI APPTEC.: BUSINESS SEGMENT
TABLE 33. WUXI APPTEC.: GEOGRAPHIC SEGMENT
TABLE 34. WUXI APPTEC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 35. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
TABLE 36. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
TABLE 37. THERMO FISHER SCIENTIFIC: PRODUCT PORTFOLIO
TABLE 38. THERMO FISHER SCIENTIFIC: BUSINESS SEGMENT
TABLE 39. THERMO FISHER SCIENTIFIC: GEOGRAPHIC SEGMENT
TABLE 40. THERMO FISHER SCIENTIFIC INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 41. BRUKER: COMPANY SNAPSHOT
TABLE 42. BRUKER: OPERATING SEGMENTS
TABLE 43. BRUKER: PRODUCT PORTFOLIO
TABLE 44. BRUKER: BUSINESS SEGMENT
TABLE 45. BRUKER: GEOGRAPHIC SEGMENT
TABLE 46. BRUKER: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 47. PERKINELMER INC.: COMPANY SNAPSHOT
TABLE 48. PERKINELMER INC.: OPERATING SEGMENTS
TABLE 49. PERKINELMER INC.: PRODUCT PORTFOLIO
TABLE 50. PERKINELMER INC.: BUSINESS SEGMENT
TABLE 51. PERKINELMER INC.: GEOGRAPHIC SEGMENT
TABLE 52. PERKINELMER INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 53. ENZO BIOCHEM INC.: COMPANY SNAPSHOT
TABLE 54. ENZO BIOCHEM INC.: OPERATING SEGMENTS
TABLE 55. ENZO BIOCHEM INC.: PRODUCT PORTFOLIO
TABLE 56. ENZO BIOCHEM INC.: BUSINESS SEGMENT
TABLE 57. ENZO BIOCHEM INC.: GEOGRAPHIC SEGMENT
TABLE 58. ENZO BIOCHEM INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 59. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 60. DANAHER CORPORATION: OPERATING SEGMENTS
TABLE 61. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 62. DANAHER CORPORATION: BUSINESS SEGMENT
TABLE 63. DANAHER CORPORATION: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 64. EUROFINS SCIENTIFIC SE: COMPANY SNAPSHOT
TABLE 65. EUROFINS SCIENTIFIC SE: PRODUCT PORTFOLIO
TABLE 66. EUROFINS SCIENTIFIC SE: GEOGRAPHIC SEGMENT
TABLE 67. EUROFINS SCIENTIFIC SE: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 68. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT
TABLE 69. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: OPERATING SEGMENTS
TABLE 70. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRODUCT PORTFOLIO
TABLE 71. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS SEGMENT
TABLE 72. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: GEOGRAPHIC SEGMENT
TABLE 73. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 74. LABCORP DRUG DEVELOPMENT.: COMPANY SNAPSHOT
TABLE 75. LABCORP DRUG DEVELOPMENT.: OPERATING SEGMENTS
TABLE 76. LABCORP DRUG DEVELOPMENT.: PRODUCT PORTFOLIO
TABLE 77. LABCORP DRUG DEVELOPMENT.: BUSINESS SEGMENT
TABLE 78. LABCORP DRUG DEVELOPMENT.: GEOGRAPHIC SEGMENT
TABLE 79. LABCORP DRUG DEVELOPMENT.: KEY STRATEGIC MOVES & DEVELOPMENTS
TABLE 80. PROMEGA CORPORATION: COMPANY SNAPSHOT
TABLE 81. PROMEGA CORPORATION: PRODUCT PORTFOLIO
TABLE 82. INSPHERO AG: COMPANY SNAPSHOT
TABLE 83. INSPHERO AG: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 1. U.S. EARLY TOXICITY TESTING MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 2. U.S. IN VITRO MARKET, BY TECHNIQUE, 2022-2030, MILLION USD
FIGURE 3. U.S. EARLY TOXICITY TESTING MARKET, BY TOXICITY ENDPOINTS, 2022-2030, MILLION USD
FIGURE 4. U.S. EARLY TOXICITY TESTING MARKET, BY END USER, 2022-2030, MILLION USD
FIGURE 5. INOTIV INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 6. INOTIV INC: PRIMARY MARKET COMPETITORS
FIGURE 7. BIO-RAD LABORATORIES INC CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 8. BIO-RAD LABORATORIES INC: PRIMARY MARKET COMPETITORS
FIGURE 9. EVOTEC A.G.: NET SALES, 2019–2021 ($MILLION)
FIGURE 10. EVOTEC A.G.: PRIMARY MARKET COMPETITORS
FIGURE 11. AGILENT TECHNOLOGIES INC: NET SALES, 2020–2022 ($MILLION)
FIGURE 12. AGILENT TECHNOLOGIES INC: PRIMARY MARKET COMPETITORS
FIGURE 13. WUXI APPTEC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 14. WUXI APPTEC: PRIMARY MARKET COMPETITORS
FIGURE 15. THERMO FISHER SCIENTIFIC: NET SALES, 2019–2021 ($MILLION)
FIGURE 16. THERMO FISHER SCIENTIFIC: PRIMARY MARKET COMPETITORS
FIGURE 17. BRUKER: NET SALES, 2019–2021 ($MILLION)
FIGURE 18. BRUKER: PRIMARY MARKET COMPETITORS
FIGURE 19. PERKINELMER INC.: NET SALES, 2020–2022 ($MILLION)
FIGURE 20. PERKINELMER INC.: PRIMARY MARKET COMPETITORS
FIGURE 21. ENZO BIOCHEM INC.: NET SALES, 2019–2021 ($MILLION)
FIGURE 22. ENZO BIOCHEM INC.: PRIMARY MARKET COMPETITORS
FIGURE 23. DANAHER CORPORATION: NET SALES, 2020–2022 ($MILLION)
FIGURE 24. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 25. EUROFINS SCIENTIFIC SE CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 26. EUROFINS SCIENTIFIC SE: PRIMARY MARKET COMPETITORS
FIGURE 27. CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 28. CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: PRIMARY MARKET COMPETITORS
FIGURE 29. LABCORP DRUG DEVELOPMENT. CO: NET SALES, 2020–2022 ($MILLION)
FIGURE 30. LABCORP DRUG DEVELOPMENT.: PRIMARY MARKET COMPETITORS
FIGURE 31. PROMEGA CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 32. INSPHERO AG: PRIMARY MARKET COMPETITORS